Proton pump inhibitors and statins: a possible interaction that favors low-density lipoprotein cholesterol reduction?

about

Proton pump inhibitors and statins: a possible interaction that favors low-density lipoprotein cholesterol reduction?

Item

http://www.wikidata.org/entity/Q39335694

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Proton pump inhibitors and sta ...... protein cholesterol reduction?

@en

Proton pump inhibitors and sta ...... protein cholesterol reduction?

@nl

type

Item

label

Proton pump inhibitors and sta ...... protein cholesterol reduction?

@en

Proton pump inhibitors and sta ...... protein cholesterol reduction?

@nl

prefLabel

Proton pump inhibitors and sta ...... protein cholesterol reduction?

@en

Proton pump inhibitors and sta ...... protein cholesterol reduction?

@nl

P1476

Proton pump inhibitors and sta ...... protein cholesterol reduction?

@en

P2093

E Klouras

http://www.w3.org/2001/XMLSchema#string

F Barkas

http://www.w3.org/2001/XMLSchema#string

M Elisaf

http://www.w3.org/2001/XMLSchema#string

M S Kostapanos

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update

Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse

Rhabdomyolysis causing AV blockade due to possible atorvastatin, esomeprazole, and clarithromycin interaction.

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review.

Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?

Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.

Exploring the path of Mediterranean diet on 10-year incidence of cardiovascular disease: the ATTICA study (2002-2012).

P304

332-337

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Evangelos N Liberopoulos

C Rizos

P577

2015-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27688698

http://www.w3.org/2001/XMLSchema#string

P921

lipoprotein

P932

5033144

http://www.w3.org/2001/XMLSchema#string